profit from every $100 of sales.
$0$100
Indaptus Therapeutics
$3.21+10.69% today
+18.0% in 1 year
1-year low $0.941-year high $4.75
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Indaptus Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$20.8 million of profit last year.
SalesProfit
Indaptus Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Indaptus Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Indaptus Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -15 | -16 | -15 | -20 | |
| -15 | -16 | -15 | -20 | |
| -14 | -15 | -15 | -21 | |
| -48.44 | -51.24 | -45.08 | -21.58 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 28 | 15 | 7 | 9 |
| Cash | 10 | 13 | 6 | 9 |
| Total debt | 0 | 0 | 0 | 0 |
| Total liabilities | 3 | 3 | 3 | 6 |
| 25 | 12 | 4 | 3 | |
| 0 | 0 | 0 | 1 | |
| -47.7% | -105.6% | -301.3% | -497.2% | |
| -58.2% | -127.7% | -380.8% | -661.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -13 | -13 | -12 | -15 | |
| – | – | – | – | |
| -13 | -13 | -12 | -15 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 3 | 3 | 2 | 1 |
Valuation
- –
- –
- –
- 1.3×
- –
- –
- 0.2×
- -3.5%
- -4.9%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -629.3%
- -247.9%
- -938.7%
- -223.9%
- -629.3%
- –
Growth
- –
- –
- −20.3%
- –
- −30.3%
Financial health
- -0.4×
- 0.00
- 0.0%
- –
- 1.51
- 1.51
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 888
Bottom 21%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -0.23 | -1.87 | +87.7% |
| Mar 17, 2026 | -3.10 | -4.36 | +28.9% |
| Nov 12, 2025 | -2.98 | -4.17 | +28.5% |
| Aug 13, 2025 | -9.09 | -9.24 | +1.6% |
| May 14, 2025 | -8.96 | -11.48 | +22.0% |
| Mar 13, 2025 | -0.38 | -0.41 | +7.3% |
| Nov 12, 2024 | -0.32 | -0.47 | +31.9% |
| Aug 12, 2024 | -0.47 | -0.54 | +13.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
33No pass
Benjamin Graham
51No pass
Philip Fisher
40No pass
Peter Lynch
60Pass
Joel Greenblatt
67Pass
Charlie Munger
48No pass
Terry Smith
45No pass
Questions about Indaptus Therapeutics
Is Indaptus Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Indaptus Therapeutics AI analysis
What does Indaptus Therapeutics do?
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. It is in Biotechnology.
Does Indaptus Therapeutics pay a dividend?
No. Indaptus Therapeutics does not pay a dividend at the moment.
Is Indaptus Therapeutics stock halal?
Yes. Indaptus Therapeutics passes our halal screen: its business is permitted and its debt is 0% of its market value, under the 30% limit. How we check
How has Indaptus Therapeutics stock done over the past year?
Up 18.0% over the past twelve months, to $3.21. It traded between $0.94 and $4.75 and is 32.4% below its high.
Who are Indaptus Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Indaptus Therapeutics's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.